Dr. Tahseen Mozaffar is a Professor of Neurology and Pathology and Laboratory Medicine and the Director, Division of Neuromuscular Disorders in the Department of Neurology at University of California, Irvine. He is the Director of the UC Irvine-MDA ALS and Neuromuscular Center. He is the Associate Director for UCI's Clinical Translational Sciences Award (CTSA). Additionally, Dr. Mozaffar serves as chair of one of the biomedical committees and the institutional liaison for Trials Innovation Hub for the Center for Translational Sciences Award (CTSA) at University of California, Irvine. He is the Principal Investigator for UCI-NEXT, the NeuroNEXT award to the University of California, Irvine, one of 25 such NeuroNEXT sites funded by the NINDS/NIH. He is also the Lead Investigator for INSPIRE-IBM, an NIH funded multicenter study on the natural history of IBM. He graduated medical school at the Aga Khan University in Karachi, Pakistan in 1989. After a rotating internship in Internal Medicine and General Surgery at the Aga Khan University Hospital, he came to the US for neurology residency training. He completed neurology residency training at Barnes Hospital in St. Louis, Missouri in 1995 and then completed a two clinical and research fellowship in Neuromuscular Disorders at Washington University in 1997. After a three-year faculty appointment at the Aga Khan University in Karachi, Pakistan, Dr. Mozaffar returned to the US and was appointed as Assistant Professor of Neurology and Director, UC Irvine Neuromuscular Program University of California, Irvine in 2000, where he has built a nationally recognized clinical and research program in Neuromuscular Disorders. He is actively involved in clinical and translational research in Neuromuscular Disorders, including serving as Principal Site Investigator on over a dozen clinical trials in ALS and other neuromuscular disorders. He has over 190 peer-reviewed publications and has authored or co-authored over a dozen book chapters and invited reviews. He was involved in planning for a Phase I/II trial of human embryonic stem cell derived human motor neuron progenitor cells in ALS through California Stem Cell Inc. Dr. Mozaffar has led a multicenter investigator initiated study on prevalence of Late-Onset Pompe disease in academic neuromuscular practices (IPANEMA study) and is the Principal Investigator for another multicenter natural history study in IBM that is pending NIH grant approval. He has been the PI for over 30 clinical studies/trials over the last decade and is generally regarded as one of the premier clinical trials investigator in neuromuscular disorders, having built from scratch the busiest in the region and nationally one of the best regarded clinical trials unit in neuromuscular disorders. He is the Director of the nationally recognized Annual UC Irvine Neuromuscular Colloquia, now in its 11th year of existence and Director of the Annual Neuromuscular Pathology Colloquium, now in its 6th year. He serves on the medical advisory board for The Myasthenia Gravis Foundation of California and the Myasthenia Gravis Foundation of America. He serves on the board of directors and scientific advisory board for the Neuromuscular Disease Foundation (NDF), a disease specific foundation for GNE Myopathy and also serves on the medical advisory board for the Myositis Association, and the MAB liaison to the Board of Directors at TMA. He has served on multiple advisory boards for the industry sponsors, including Alexion, Amicus, Alnylam, Audentes, Bioblast, CSL, Genzyme, Grifols, MT-Pharma, Sarepta and Ultragenyx. He serves on a global advisory board for Pompe at Amicus and for Spark Therapeutics. He serves on multiple Data Safety Monitoring Board for industry and NIH. He is a standing reviewer for the ETTN study section at the NIH. Dr. Mozaffar’s basic science research interest include understanding nerve degeneration after compression neuropathies and muscle atrophy paradigms in a variety of human neurological disorders. His clinical research interest are in rare and orphan muscle disorders, include Pompe Disease, GNE myopathy, OPMD and Limb-Girdle Muscular Dystrophies. He is also very involved in the myositis field, especially Antibody-Associated Myositides and Inclusion Body Myositis.